BR112021018930A2 - Miriquizumabe para uso em um método de tratamento de doença de crohn - Google Patents

Miriquizumabe para uso em um método de tratamento de doença de crohn

Info

Publication number
BR112021018930A2
BR112021018930A2 BR112021018930A BR112021018930A BR112021018930A2 BR 112021018930 A2 BR112021018930 A2 BR 112021018930A2 BR 112021018930 A BR112021018930 A BR 112021018930A BR 112021018930 A BR112021018930 A BR 112021018930A BR 112021018930 A2 BR112021018930 A2 BR 112021018930A2
Authority
BR
Brazil
Prior art keywords
disease
miriquizumab
treating crohn
crohn
treatment
Prior art date
Application number
BR112021018930A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Tuttle Jay
Frederick POLLACK Paul
William Friedrich Stuart
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112021018930A2 publication Critical patent/BR112021018930A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112021018930A 2019-04-22 2020-04-15 Miriquizumabe para uso em um método de tratamento de doença de crohn BR112021018930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
BR112021018930A2 true BR112021018930A2 (pt) 2022-01-18

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018930A BR112021018930A2 (pt) 2019-04-22 2020-04-15 Miriquizumabe para uso em um método de tratamento de doença de crohn

Country Status (16)

Country Link
US (1) US20220040299A1 (https=)
EP (1) EP3958897B1 (https=)
JP (3) JP7297930B2 (https=)
KR (2) KR102869852B1 (https=)
CN (2) CN113677366A (https=)
AU (2) AU2020263238C1 (https=)
BR (1) BR112021018930A2 (https=)
EA (1) EA202192532A1 (https=)
IL (2) IL286818B2 (https=)
MA (1) MA55756A (https=)
MX (1) MX2021012848A (https=)
SG (1) SG11202110619XA (https=)
TW (2) TW202515610A (https=)
UA (1) UA128657C2 (https=)
WO (1) WO2020219314A1 (https=)
ZA (1) ZA202108094B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
SG11201507483PA (en) 2013-03-15 2015-10-29 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
US20190292265A1 (en) * 2016-08-19 2019-09-26 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
EA202192532A1 (ru) 2022-01-21
IL286818A (en) 2021-10-31
MX2021012848A (es) 2021-12-10
IL286818B2 (en) 2026-03-01
IL324048A (en) 2025-12-01
JP7761614B2 (ja) 2025-10-28
NZ781127A (en) 2025-06-27
JP2025148449A (ja) 2025-10-07
CN113677366A (zh) 2021-11-19
AU2020263238B2 (en) 2023-08-17
ZA202108094B (en) 2025-05-28
JP2022530397A (ja) 2022-06-29
CN119700968A (zh) 2025-03-28
KR20210142704A (ko) 2021-11-25
WO2020219314A1 (en) 2020-10-29
KR20250153865A (ko) 2025-10-27
KR102869852B1 (ko) 2025-10-14
UA128657C2 (uk) 2024-09-18
TW202515610A (zh) 2025-04-16
AU2020263238A1 (en) 2021-11-04
JP7297930B2 (ja) 2023-06-26
MA55756A (fr) 2022-03-02
EP3958897B1 (en) 2026-05-06
AU2020263238C1 (en) 2024-02-22
EP3958897A1 (en) 2022-03-02
JP2023116680A (ja) 2023-08-22
CA3134587A1 (en) 2020-10-29
TW202103734A (zh) 2021-02-01
TWI850365B (zh) 2024-08-01
SG11202110619XA (en) 2021-11-29
US20220040299A1 (en) 2022-02-10
AU2023265759A1 (en) 2023-12-07
IL286818B1 (en) 2025-11-01

Similar Documents

Publication Publication Date Title
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
ZA202005388B (en) Methods of treating ulcerative colitis
BR112015025803A2 (pt) método para tratar um substrato animal
BR112018003984A2 (pt) anticorpos
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
BR112017023576A2 (pt) Método para tratar uma disfunção proliferativa de células b
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
BR112016002198A2 (pt) métodos de tratamento de miosite por corpos de inclusão esporádica
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
EA201792545A1 (ru) Способы и наборы для лечения депрессии
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
MX381139B (es) Anticuerpo anti-notch4 humano.
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2025003476A (es) Anticuerpos anti-il-27 y usos de los mismos
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2018016332A (es) Quimioterapias de combinacion.
BR112022007216A2 (pt) Métodos para tratamento de linfoma difuso, kit e imunoconjugado